Partnered with Welt to apply Decentralized Clinical Trials (DCT) to digital treatments for insomnia for the first time in Korea.
JNPMEDI, a medical data platform company, announced on the 19th that it will apply its self-developed Decentralized Clinical Trials (hereinafter referred to as DCT) solution "Maven DCT Suite" to the Investigational Device Exemption (IDE), a digital treatment for insomnia with Welt.
Activation of the 'Decentralized Clinical Trials (DCT)' market worldwide after the pandemic. Interest in DCT has also increased in the domestic market. When applying DCT, which has been digitally converted to the clinical trial process, it is expected to reduce cost and time as well as increase accuracy.
In partnership with JNPMEDI and Welt, it will open a new market in the domestic clinical trial industry. The first step was to start with a digital cure for insomnia.
JNPMEDI will continue to create various cases of DCT application to prove the value of digitalization utility in the clinical market.
JNPMEDI and Welt are planning to apply their own decentralized clinical trial (DCT) solution to confirmation clinical trials for digital treatment of insomnia.
While the digital transformation of clinical trials is emerging as an important paradigm around the world, digital clinical trials based on domestic technology are applied to digital treatment of insomnia for the first time in Korea, drawing attention.
JNPMEDI, a medical data platform company, announced on the 19th that it will apply its self-developed decentralized clinical trials (hereinafter referred to as DCT) solution "Maven DCT Suite" to confirmation clinical trials for digital treatments for insomnia by digital healthcare company Welt. The Maven DCT suite is a world-class clinical trial platform that is attracting attention as a new alternative to lead the next-generation clinical industry with high technology such as convenient data collection, high hit rate analysis accuracy, optimized interface, and blockchain-based reliability.
The DCT study of the digital treatment of insomnia (Digital treatment of Insomnia) will be studied together with Yonsei University's Shinchon Severance Hospital. After installing an application-type digital treatment developed by Welt on a smartphone, the entire clinical process under follow-up by researchers will be studied and conducted through the Maven DCT suite. After being recruited through SNS, clinical trial subjects go through a screening process to select suitability, participate in clinical trials through eConsent (electronic informed consultant) for electronic consent, and eCOA (clinical outcome assessment) that collects clinical data using mobile devices, and most of the processes are conducted non-face-to-face to minimize hospital visits.
Until now, the demand for decentralized digitalization has increased in the field of clinical trials, but there have been many limitations in market expansion, such as staying in traditional clinical methods due to unresolved regulations and unexplored environments or relying on expensive foreign solutions overseas.
The DCT (Decentralize Clinical Trial) is a non-face-to-face clinical trial process from recruitment to consent to participation, data collection, monitoring, and prescription. It has been noted as a key factor in advancing the clinical trial industry. With the arrival of COVID-19, voices for the need for DCT have been raised as it has been difficult in various parts of the medical and health industry due to the delay in clinical trials.